Fresenius SE & Co. KGaA (FRE.DE)
Chart Events
Performance Outlook
| Previous Close | 24.55 |
| Open | 24.80 |
| Bid | 24.46 x N/A |
| Ask | 24.51 x N/A |
| Day's Range | 24.23 - 24.85 |
| 52 Week Range | 23.40 - 47.60 |
| Volume | |
| Avg. Volume | 1,207,283 |
| Market Cap | 13.72B |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | 7.64 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.92 (3.75%) |
| Ex-Dividend Date | May 16, 2022 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for FRE.DE
Related Research
- Reuters
Fresenius Medical shares at 12-year low as labour costs weigh on profit
(Reuters) -Shares in the world's largest kidney dialysis provider Fresenius Medical Care (FMC) plunged more than 12% to a 12-year low on Thursday after it cut its earnings outlook as costs surge and a U.S. staff shortage leaves it scrambling for nurses. In an unscheduled statement late on Wednesday, FMC flagged a decline in net income approaching 20% this year and withdrew its 2025 targets. Most of its U.S. patients are covered by state-run insurer Medicare, with lump-sum reimbursements per patient that only get adjusted to cost inflation with a two-year delay, the chief executive of FMC parent Fresenius, Stephan Sturm, said on an analyst call.
- Zacks
After Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)
The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
